全文获取类型
收费全文 | 125486篇 |
免费 | 9451篇 |
国内免费 | 3609篇 |
专业分类
耳鼻咽喉 | 989篇 |
儿科学 | 2327篇 |
妇产科学 | 1781篇 |
基础医学 | 6987篇 |
口腔科学 | 2871篇 |
临床医学 | 15092篇 |
内科学 | 18815篇 |
皮肤病学 | 2309篇 |
神经病学 | 6418篇 |
特种医学 | 4126篇 |
外国民族医学 | 39篇 |
外科学 | 12395篇 |
综合类 | 18193篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5265篇 |
眼科学 | 2050篇 |
药学 | 10149篇 |
79篇 | |
中国医学 | 11144篇 |
肿瘤学 | 17492篇 |
出版年
2024年 | 316篇 |
2023年 | 2248篇 |
2022年 | 4119篇 |
2021年 | 5539篇 |
2020年 | 5227篇 |
2019年 | 4733篇 |
2018年 | 4384篇 |
2017年 | 4858篇 |
2016年 | 5154篇 |
2015年 | 4935篇 |
2014年 | 8932篇 |
2013年 | 11327篇 |
2012年 | 7302篇 |
2011年 | 7792篇 |
2010年 | 6446篇 |
2009年 | 5924篇 |
2008年 | 5796篇 |
2007年 | 6222篇 |
2006年 | 5563篇 |
2005年 | 4948篇 |
2004年 | 4012篇 |
2003年 | 3633篇 |
2002年 | 2980篇 |
2001年 | 2631篇 |
2000年 | 2185篇 |
1999年 | 1709篇 |
1998年 | 1414篇 |
1997年 | 1191篇 |
1996年 | 986篇 |
1995年 | 891篇 |
1994年 | 699篇 |
1993年 | 540篇 |
1992年 | 483篇 |
1991年 | 441篇 |
1990年 | 377篇 |
1989年 | 329篇 |
1988年 | 322篇 |
1987年 | 276篇 |
1986年 | 217篇 |
1985年 | 255篇 |
1984年 | 223篇 |
1983年 | 165篇 |
1982年 | 164篇 |
1981年 | 163篇 |
1980年 | 129篇 |
1979年 | 121篇 |
1978年 | 65篇 |
1977年 | 42篇 |
1976年 | 49篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Abstract: The optimal timing of systemic cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy and local radiation in adjuvant breast cancer has been a debatable subject. To evaluate the Lankenau Hospital experience with sequential CMF chemotherapy followed by radiation in the adjuvant therapy of stage I and stage II breast cancer we reviewed the records of patients at our center. This group of 34 patients was treated in a homogenous manner, all receiving standard CMF for six cycles followed by radiotherapy after lumpectomy with axillary lymph node dissection. The radiation course was 5040cGy to the entire breast (28 fractions in 45 elapsed days) followed by a boost to the tumor site of 1800cGy in 10 fractions. Thirty-four patients were identified and followed for an average of 5 years (range 1.5–11.5 years). One patient had local recurrence and with subsequent treatment is disease-free at 5 years postrecurrence (8 years from initial diagnosis). Two deaths were not breast-cancer related (1 myocardial infarction at year 3, 1 melanoma at year 7.5). The estimated probability of no relapse at 5 years and 8 years by Kaplan-Meier analysis is 79% and 60% respectively. Overall and disease-free survival in this group of patients treated with breast-conserving surgery and CMF chemotherapy followed by radiation is excellent. There appears to be no detriment to delaying radiotherapy until full doses of systemic treatment are given as local recurrence was rare (6%) and was amenable to further treatment. 相似文献
52.
光动力学疗法与局部化疗联合治疗进展期食管贲门癌 总被引:2,自引:0,他引:2
作应用光动力学疗法(PDT)对进展期食管贲门癌55例进行治疗,并对其中15例联合应用内镜下局部注射抗癌药物。对每一患均先静脉滴注血卟啉衍生物(HPD)5mg/kg,于用药后24,48和72h分别用波长630nm的铜蒸汽激光照射肿瘤部位。联合治疗组除PDT治疗外,于每次光照前肿瘤局部注射5-Fu250~500mg。结果:联合治疗组的近期显效率高于单纯PDT组(P〈0.05)。病例随访6~16月, 相似文献
53.
Recombinant human deoxyribonuclease I (rhDNase) is a new therapeutic agent developed to improve clearance of purulent sputum from the human airways. It is delivered by inhalation. Four jet nebulizers, T Up-Draft II (Hudson), Customized Respirgard II (Marquest), Acorn II (Marquest), and Airlife Misty (Baxter), were evaluated in vitro for their ability to deliver aerosols of rhDNase. The aerosols were generated from 2.5-mL aqueous solutions of rhDNase, at concentrations of either 1 or 4 mg/mL. In all experiments, the Pulmo-Aide Compressor (De Vilbiss) was used to supply the air to the nebulizers. Between 20 and 28% of the rhDNase dose initially placed in the nebulizers was delivered to the mouthpiece in the respirable range (1-6 µm). Evaluation of the rhDNase following nebulization in all four devices indicated that there was no loss in enzymatic activity and no increase in aggregation. Circular dichroism spectrophotometry indicated there was no change in either the secondary or the tertiary structure in rhDNase following nebulization. These results show that all four nebulizers are essentially equivalent in their ability to deliver respirable doses of rhDNase in an intact, fully active form. Changing the concentration of the solution in the nebulizer from 4 to 1 mg/mL rhDNase leads to a proportional reduction in the respirable dose delivered to the mouthpiece. 相似文献
54.
前列腺癌去雄激素治疗不良反应的预防和处理 总被引:1,自引:0,他引:1
目的观察去雄激素治疗前列腺癌的不良反应,并探讨其预防和治疗。方法回顾性分析1998年7月-2006年1月112例去雄激素治疗晚期前列腺癌的临床资料。结果112例患者中,97例完成了不良反应的调查。随访3-36月,去雄激素治疗后潮热、性功能障碍、病理性骨折发生率分别为46%、75%、4%;患者潮热、精神疲乏、四肢乏力、纳差症状明显加重(P<0.05);性功能明显减退(P<0.05)。12例潮热症状严重者使用抗抑郁药博乐欣(25mg,tid)1-2周症状减轻。7例有骨转移性疼痛或严重骨质疏松患者,应用唑来膦酸4mg静脉滴注,每45d一次,骨痛症状缓解。结论去雄激素对前列腺癌患者生活质量有一定影响。博乐欣可减轻患者潮热症状,唑来膦酸可预防和治疗去雄激素相关的骨质疏松并发症。 相似文献
55.
Madhuri Dadwal Chander Mohan D. R. Sharma 《Indian journal of otolaryngology and head and neck surgery》2007,59(3):261-263
Secondary tuberculosis of pharynx is a rare condition as pharynx is not a common site for clinically manifest tuberculosis.
A rare and unusual case of secondary oropharyngeal tuberculosis in a 40 years male patient, who presented with an ulceroproliferative
lesion of oropharynx extending to nasopharynx and laryngopharynx is being reported. 相似文献
56.
J. R. Zahar M. Lecuit E. Carbonnelle F. Ribadeau-Dumas X. Nassif O. Lortholary 《Clinical microbiology and infection》2007,13(3):219-221
Until recently, most reported cases of bacteraemia caused by multidrug-resistant strains of Enterobacteriacae producing an extended-spectrum beta-lactamase (ESBL) in Europe have been nosocomial in origin. However, increasing numbers of reports of community-acquired bacteraemia and urinary tract infection caused by ESBL-producing microorganisms suggest that the geographical origin of patients should be taken into account as a risk-factor for possible ESBL production. Early identification of patients at high-risk of infection with ESBL-producing microorganisms, based on their geographical origin and travel history, should help to optimise initial antibiotic treatment strategies for severe urinary tract infections in Europe. 相似文献
57.
目的:研究复方保元煎对绝经后冠心病(CHD)患者脂代谢、血流变的影响。方法:观察180例患者,随机分为治疗组102例,对照组78例。治疗组采用中药复方保元煎治疗,对照组采用维尼安治疗,分别于治疗前后测定脂代谢、血流变指标。结果:治疗后两组脂代谢、血流变指标均有不同程度的改变。治疗组在降低总胆固醇(TC)、甘油三酯(TG),低密度脂蛋白(LDL-C)、载脂蛋白B(apoB)、血流变指标优于对照组(P<0.05或P<0.01)。结论:复方保元煎能改变血脂代谢、调节血黏度,对预防和逆转绝经后的CHD的发生和发展有积极的治疗作用。 相似文献
58.
Rauhut Friedhelm Reinhardt Volker Budach Volker Wiedemayer Helmut Nau Heinz-Eugen 《Neurosurgical review》1989,12(4):309-313
Ten patients suffering from intramedullary pilocytic astrocytomas (WHO-classification: astrocytoma grade I) were investigated catamnesticly. Combined surgery and radiotherapy was performed. Seven patients received neutron irradiation postoperatively. In four cases the neurological symptoms were improved after follow-up periods ranging from 33 to 89 months. The three other patients died after 6 to 21 months. The autopsy findings of a 14 year old child are presented. Our results are compared with reports in the literature. In addition, long-term problems of the spinal column are discussed. It seems that the combined surgical and neutron therapy improves the prognosis of pencil gliomas. 相似文献
59.
目的:通过超声热疗配合常规放疗治疗晚期恶性肿瘤的临床研究,评价超声热疗的疗效及与疗效有关的加热参数。材料和方法: 对17 例晚期恶性肿瘤的17 个病灶用常规放疗加超声热疗。放疗用直线加速器外照射,每次2 Gy、周5 次, 总剂量40~70 Gy。热疗在放疗后30 m in 内进行,每周加热1~2 次,每次加温时间 60 m in,6~8 次一疗程。全例病人每次加温时实测肿瘤内温度。结果:在可评价的13例中,CR 23.1% (3/13)、PR 46.2% (6/13)、NC 23.1% (3/13)、PD 7.7% ( 1/13) , 有效率(CR+ PR)为69.3% 。肿瘤中心部温度达到42.5℃以上的累积时间和总加热次数是决定疗效的重要参数。在17 例患者的 89 次加温中,副作用的发生率相对较低。结论:使用超声热疗配合放疗,只要实现满负荷加温,进一步提高肿瘤的局部控制率是完全可能的 相似文献
60.
Fatoş Yalçınkaya Necmiye Tümer Nilgün Çakar Nuray Özkaya 《Pediatric nephrology (Berlin, Germany)》1997,11(3):350-352
Hypertension is one of the most important complications of erythropoietin (rHuEPO) therapy in dialysis patients. In this
study, the effect of two different dosage regiments of subcutaneous rHuEPO on blood pressure [BP] was evaluated in 20 anemic
children on continuous ambulatory peritoneal dialysis (CAPD). Patients were randomized to receive rHuEPO 50 U/kg, either once
a week (group 1, 50 U/kg per week) or three times a week (group 2, 150 U/kg per week). At the beginning of the study, 8 patients
in group 1 and 8 patients in group 2 were on antihypertensive therapy. In group 1, the hematocrit increased gradually and
significantly from 18.98%±1.79% to 30.1%±1.62% after 6 months, while in group 2 it rapidly increased from 19.53%±1.86% to
32.4%±1.11% after 3 months. A significant increase in the mean arterial BP was observed in group 2. Antihypertensive therapy
had to be increased in all of the 8 previously hypertensive patients and had to be initiated in 1 of the 2 originally normotensive
patients in the same group. None of the patients in group 1 required a change in antihypertensive medication. We conclude
that during treatment with rHuEPO pre-existing hypertension and the dose of rHuEPO are the most important risk factors for
the development or worsening of hypertension in children on CAPD, and gradual elevation of hematocrit by low-dose rHuEPO avoids
the development of severe hypertension.
Received December 11, 1995; received in revised form September 16, 1996; accepted September 19, 1996 相似文献